Investor mix
2 investors on record; lead investors include Qianhai Ark Asset Management; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 50% |
| Bank & private debt | 1 | 50% |
Developer of CAR-T cell based immunotherapy for cancer
2 investors on record; lead investors include Qianhai Ark Asset Management; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 50% |
| Bank & private debt | 1 | 50% |